SCHEMBL4483948

SCHEMBL4483948

CC(=O)N(CCN(C)C)c1ccc(N/C(=C2\C(=O)Nc3cc(Cl)ccc32)c2ccc(O)cc2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIMK1 P53667 1/20 0.36
LRRK2 Q5S007 2/20 0.36
NPC1 O15118 1/20 0.34
POLB P06746 1/20 0.34
AHR P35869 1/20 0.34
IDO1 P14902 2/20 0.33
TDO2 P48775 2/20 0.33
CHEK1 O14757 1/20 0.33
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
PDK2 Q15119 1/20 0.33
PDK4 Q16654 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4483954 1.00 LIMK1 (0.36) LIMK1LRRK2NPC1POLBAHR
SCHEMBL226587 0.96 LIMK1 (0.39) LIMK1LRRK2NPC1POLBAHR
SCHEMBL226588 0.96 LIMK1 (0.39) LIMK1LRRK2NPC1POLBAHR
SCHEMBL4488448 0.95 LRRK2 (0.35) LIMK1LRRK2NPC1POLBAHR
SCHEMBL4488452 0.95 LRRK2 (0.35) LIMK1LRRK2NPC1POLBAHR
SCHEMBL4492738 0.94 LRRK2 (0.42) LIMK1LRRK2NPC1POLBAHR
SCHEMBL4492731 0.94 LRRK2 (0.42) LIMK1LRRK2NPC1POLBAHR
SCHEMBL4491326 0.92 LIMK1 (0.37) LIMK1LRRK2NPC1POLBAHR
SCHEMBL4491323 0.92 LIMK1 (0.37) LIMK1LRRK2NPC1POLBAHR
SCHEMBL4491553 0.92 LIMK1 (0.37) LIMK1LRRK2NPC1POLBAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR LIMK1 312/4885LRRK2 168/4885NPC1 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.